The design of viral clearance studies must keep pace with the quickly evolving biologic drugs industry.
Tareq Jaber
Advertisement
Tareq Jaber, tareq.jaber@crl.com, is associate director at Charles River Laboratories.
Articles by Tareq Jaber
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
China Grants Ivonescimab Priority Review in Biliary Tract Cancer
2
Spyre’s Anti-TL1A Antibody SPY072 Misses in Psoriatic Arthritis and Axial Spondyloarthritis, Shifts Focus to Hidradenitis Suppurativa
3
Caldera’s IL-23p19×TL1A Bispecific CLD-423 Shows 40-Day Half-Life in Phase 1a, Supporting Dosing Every 8 to 12 Weeks
4
VeonGen Aligns with FDA on Phase 3 Design for Stargardt Gene Therapy
5